FR2826261A1 - COMPOSITION FOR TOPICAL USE COMPRISING A CYTOTOXIC PRODUCT AND ITS USE IN THE TREATMENT OF ALOPECHE - Google Patents
COMPOSITION FOR TOPICAL USE COMPRISING A CYTOTOXIC PRODUCT AND ITS USE IN THE TREATMENT OF ALOPECHE Download PDFInfo
- Publication number
- FR2826261A1 FR2826261A1 FR0108399A FR0108399A FR2826261A1 FR 2826261 A1 FR2826261 A1 FR 2826261A1 FR 0108399 A FR0108399 A FR 0108399A FR 0108399 A FR0108399 A FR 0108399A FR 2826261 A1 FR2826261 A1 FR 2826261A1
- Authority
- FR
- France
- Prior art keywords
- composition
- composition according
- hair growth
- cytotoxic product
- cytotoxic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 231100000433 cytotoxic Toxicity 0.000 title claims abstract description 15
- 230000001472 cytotoxic effect Effects 0.000 title claims abstract description 15
- 230000000699 topical effect Effects 0.000 title claims abstract description 11
- 239000002537 cosmetic Substances 0.000 claims abstract description 13
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims abstract description 8
- 229960003048 vinblastine Drugs 0.000 claims abstract description 8
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims abstract description 8
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 7
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 7
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 7
- 230000003779 hair growth Effects 0.000 claims description 15
- 201000004384 Alopecia Diseases 0.000 claims description 11
- 231100000360 alopecia Toxicity 0.000 claims description 7
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 5
- 229960004316 cisplatin Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 230000000259 anti-tumor effect Effects 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 239000002453 shampoo Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 abstract description 3
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 abstract 2
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 abstract 1
- QKGJFQMGPDVOQE-HWKANZROSA-N raphanin Chemical compound CS(=O)\C=C\CCN=C=S QKGJFQMGPDVOQE-HWKANZROSA-N 0.000 abstract 1
- 229960005559 sulforaphane Drugs 0.000 abstract 1
- 235000015487 sulforaphane Nutrition 0.000 abstract 1
- QKGJFQMGPDVOQE-JTQLQIEISA-N sulforaphene Natural products C[S@](=O)C=CCCN=C=S QKGJFQMGPDVOQE-JTQLQIEISA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 6
- 210000004209 hair Anatomy 0.000 description 6
- 230000003797 telogen phase Effects 0.000 description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 229930182912 cyclosporin Natural products 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 208000024963 hair loss Diseases 0.000 description 3
- 230000003676 hair loss Effects 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020864 Hypertrichosis Diseases 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 241000101040 Pityriasis Species 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- -1 serums Substances 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
Description
<Desc/Clms Page number 1> <Desc / Clms Page number 1>
La présente invention concerne une composition plus particulièrement cosmétique, destinée au traitement des alopécies et des états apparentés, l'utilisation d'une composition pour la fabrication d'un médicament pour traiter ces désordres ainsi qu'un procédé de traitement cosmétique. The present invention relates to a more particularly cosmetic composition, intended for the treatment of alopecia and related conditions, the use of a composition for the manufacture of a medicament for treating these disorders as well as a cosmetic treatment method.
La chute des cheveux peut être provoquée par des causes diverses telles que l'âge, une pathologie (pityriasis capitis), une agression extérieure (décoloration ou teinture). Elle peut être locale ou généralisée, et peut engendrer un simple désagrément d'ordre esthétique ou constituer une véritable pathologie. Hair loss can be caused by various causes such as age, pathology (pityriasis capitis), external aggression (discoloration or dyeing). It can be local or generalized, and can cause a simple aesthetic inconvenience or constitute a real pathology.
Un certain nombre de produits ont été proposés dans le passé pour stimuler la pousse des cheveux tant chez l'homme que chez la femme, mais aucun à ce jour n'a abouti à un résultat net dans une proportion importante de la population soumise au traitement. A number of products have been proposed in the past to stimulate hair growth in both men and women, but none to date has resulted in a net result in a significant proportion of the population undergoing treatment. .
Il a été proposé des produits irritants (capsaïcine) ou vasodilateurs (pilocarpine) et aussi plus récemment des molécules antihypertensives (minoxidil et dérivés). Ces derniers produits se sont avérés provoquer une hypertrichose chez les patients traités pour une hypertension par voie systématique et stimuler la pousse des cheveux par voie topique chez les patients présentant une alopécie débutante ou plus ancienne. It has been proposed irritants (capsaicin) or vasodilators (pilocarpine) and also more recently antihypertensive molecules (minoxidil and derivatives). The latter products have been shown to cause hypertrichosis in patients treated for hypertension systematically and to stimulate hair growth topically in patients with early or older alopecia.
Toutefois, ces effets se sont montrés positifs sur une partie minoritaire des patients et relativement discrets dans tous les cas. However, these effects were positive in a minority of patients and relatively discreet in all cases.
Parallèlement à ces produits mis sur le marché de la cosmétique et de la pharmacie pour leurs effets réels ou supposés sur les cheveux, on peut citer aussi le cas de molécules immunodépressives, la cyclosporin et le FK506 (macrolide fongique) qui ont un effet similaire. In addition to these products placed on the cosmetic and pharmacy market for their real or supposed effects on the hair, we can also cite the case of immunosuppressive molecules, cyclosporin and FK506 (fungal macrolide) which have a similar effect.
La cyclosporin est active par voie systémique et par voie locale, alors que le FK506 n'est actif que par voie locale. Cyclosporin is active systemically and locally, while FK506 is only active locally.
<Desc/Clms Page number 2> <Desc / Clms Page number 2>
Ces produits induisent également de façon nette la pousse du poil chez la souris noire C57/B16 qui est l'animal de référence pour les études de screening de molécules actives sur la pousse des cheveux. Cette induction de la pousse se manifeste par une transition de la phase télogène des poils à la phase anagène facile à observer et à mesurer grâce à la pigmentation des poils alors que la peau de la souris en phase télogène n'est pas ou peu pigmentée. These products also clearly induce hair growth in the black C57 / B16 mouse, which is the reference animal for screening studies of active molecules on hair growth. This induction of growth is manifested by a transition from the telogen phase of the hairs to the anagen phase which is easy to observe and measure thanks to the pigmentation of the hairs while the skin of the mouse in the telogen phase is not or only slightly pigmented.
Toutefois, les effets immunodépresseurs de la cyclosporine et du FK506 ne permettent pas leur utilisation en cosmétique ou même en médecine esthétique. La dépression du système immunitaire locale pouvant induire des désordres graves au niveau cutané comme des cancers ou des infections opportunistes, ces produits ne sont guère utilisables dans ces domaines. However, the immunosuppressive effects of cyclosporine and FK506 do not allow their use in cosmetics or even in aesthetic medicine. Since the depression of the local immune system can induce serious skin disorders such as cancer or opportunistic infections, these products are hardly usable in these areas.
En conséquence, il serait très utile de disposer de produits capables de présenter un effet net sur la pousse des cheveux afin de traiter notamment les alopécies androgéniques qui représentent un des problèmes esthétiques les plus importants chez l'homme. Consequently, it would be very useful to have products capable of having a clear effect on hair growth in order to treat in particular androgenic alopecia which represent one of the most important aesthetic problems in humans.
De façon surprenante, les inventeurs ont découverts que les molécules cytotoxiques vis- à-vis des cellules mitotiques et peu cytotoxiques vis-à-vis des cellules quiescentes telles que le paclitaxel, la vinblastine, le cisplatine, déclenchent la phase anagène chez le lapin en phase télogène lors d'une application par voie topique, ce qui peut paraître paradoxal étant donné leur effet secondaire bien connu de provoquer la chute des cheveux. Il semble de plus que ce soit cet effet cytotoxique qui soit à la base de l'effet de simulation de la pousse des cheveux. Surprisingly, the inventors have discovered that cytotoxic molecules with respect to mitotic cells and little cytotoxic with respect to quiescent cells such as paclitaxel, vinblastine, cisplatin, trigger the anagen phase in rabbits. telogen phase during topical application, which may seem paradoxical given their well-known side effect of causing hair loss. It also seems that it is this cytotoxic effect which is at the basis of the effect of simulating hair growth.
C'est pourquoi la présente invention concerne une composition destinée à une application topique, caractérisée en ce qu'elle comprend à titre de principe actif au moins un produit cytotoxique dans un milieu physiologiquement acceptable et approprié pour une application topique. This is why the present invention relates to a composition intended for topical application, characterized in that it comprises, as active principle, at least one cytotoxic product in a physiologically acceptable medium suitable for topical application.
Par le terme de produit cytotoxique , on entend au sens de la présente invention tout produit cytotoxique vis-à-vis des cellules mitotiques et peu cytotoxiques By the term of cytotoxic product, one understands within the meaning of the present invention any cytotoxic product with respect to the mitotic cells and little cytotoxic
<Desc/Clms Page number 3><Desc / Clms Page number 3>
vis-à-vis des cellules quiescentes. En particulier il s'agit d'un produit ayant une activité anti-tumorale. Avantageusement le produit est choisit dans le groupe constitué par le paclitaxel, la vinblastine, le cisplatine et leurs sels physiologiquement acceptables. vis-à-vis quiescent cells. In particular it is a product having an anti-tumor activity. Advantageously, the product is chosen from the group consisting of paclitaxel, vinblastine, cisplatin and their physiologically acceptable salts.
Ces molécules peuvent en particulier être obtenus auprès de fournisseurs tels que Sigma (Paclitaxel : réf. T 7402, Vinblastine : réf. V 1377, Ciplastine : réf. P 4394). These molecules can in particular be obtained from suppliers such as Sigma (Paclitaxel: ref. T 7402, Vinblastine: ref. V 1377, Ciplastine: ref. P 4394).
Par le terme de milieu physiologiquement acceptable approprié pour une application topique , on entend au sens de la présente invention tout milieu compatible avec le principe actif et acceptable en cosmétique ou en pharmacie, notamment compatible avec la peau et le cuir chevelu. By the term physiologically acceptable medium suitable for topical application, is meant in the sense of the present invention any medium compatible with the active principle and acceptable in cosmetics or in pharmacies, in particular compatible with the skin and the scalp.
Dans un mode de réalisation particulier, la composition selon la présente invention est une composition cosmétique destinée à traiter l'alopécie, stimuler la croissance pilaire, stimuler la croissance capillaire et/ou traiter les états séborrhéiques. In a particular embodiment, the composition according to the present invention is a cosmetic composition intended to treat alopecia, stimulate hair growth, stimulate hair growth and / or treat seborrheic conditions.
Les compositions topiques, notamment cosmétiques, selon la présente invention pourront bien entendu se présenter sous les formes qui sont habituellement connues pour ce type d'administration, c'est-à-dire notamment les lotions, les mousses, les gels, les dispersions, les sérums, les sprays ou les crèmes par exemple, mais également pourront être administrées dans des shampooings, avec des excipients permettant notamment une pénétration cutanée afin d'améliorer les propriétés et l'accessibilité du principe actif. The topical compositions, in particular cosmetic compositions, according to the present invention may of course be in the forms which are usually known for this type of administration, that is to say in particular lotions, foams, gels, dispersions, serums, sprays or creams for example, but also may be administered in shampoos, with excipients allowing in particular skin penetration in order to improve the properties and accessibility of the active principle.
Ces compositions essentiellement destinées à une application topique contiennent, outre le principe actif un milieu physiologiquement acceptable, en général à base d'eau ou de solvant, par exemple des alcools, des éthers ou des glycols. These compositions essentially intended for topical application contain, in addition to the active principle, a physiologically acceptable medium, generally based on water or on a solvent, for example alcohols, ethers or glycols.
Les compositions selon la présente invention contiennent de préférence de 0,001 à 10% en poids de produit cytotoxique. The compositions according to the present invention preferably contain from 0.001 to 10% by weight of cytotoxic product.
Ces compositions peuvent également contenir : - des agents tensioactifs, - des conservateurs, - des agents stabilisants, - des émulsifiants et These compositions can also contain: - surfactants, - preservatives, - stabilizing agents, - emulsifiers and
<Desc/Clms Page number 4><Desc / Clms Page number 4>
- des épaississants. - thickeners.
Ces composants sont connus dans le domaine cosmétique, notamment pour la réalisation de compositions pour le traitement de la chute des cheveux. These components are known in the cosmetic field, in particular for the production of compositions for the treatment of hair loss.
La présente invention concerne également l'utilisation d'au moins un produit cytotoxique ou d'une composition selon la présente invention pour la fabrication d'un médicament destiné à traiter l'alopécie, les états séborrhéiques, stimuler la croissance pilaire et la croissance capillaire ou les états apparentés lorsque ceux-ci présentent un caractère pathologique. The present invention also relates to the use of at least one cytotoxic product or of a composition according to the present invention for the manufacture of a medicament intended to treat alopecia, seborrheic states, stimulate hair growth and hair growth. or related states when these are of a pathological nature.
Les médicaments contenant ces principes actifs pourront se présenter sous les formes appropriées pour leur administration, c'est-à-dire notamment des lotions, des crèmes, des sprays ou éventuellement si cela est nécessaire pourront être présentés sous des formes de type forme injectable, notamment intradermique. The drugs containing these active ingredients may be in forms suitable for their administration, that is to say in particular lotions, creams, sprays or possibly if necessary may be presented in forms of injectable form, especially intradermal.
La présente invention concerne, en outre, un procédé de traitement cosmétique tel que l'on applique de façon topique, notamment sur le cuir chevelu, une composition cosmétique selon la présente invention afin d'améliorer l'esthétique de la chevelure et/ou traiter l'alopécie. The present invention also relates to a cosmetic treatment method such as topically applied, in particular to the scalp, a cosmetic composition according to the present invention in order to improve the aesthetics of the hair and / or treat alopecia.
D'autres caractéristiques résulteront de la lecture des exemples ci-après donnés à titre indicatif non limitatif ETUDE PHARMACOLOGIQUE. Other characteristics will result from reading the examples below given for non-limiting indication PHARMACOLOGICAL STUDY.
Test sur le tapin. Tapin test.
On utilise des lapins de sexe mâle, de 12 semaines d'âge au moins et d'âge identique afin que le poil de ces derniers soient en phase télogène, ce que l'on peut vérifier par la tonte des animaux. Male rabbits, at least 12 weeks old and of identical age, are used so that their hair is in the telogen phase, which can be verified by shearing the animals.
<Desc/Clms Page number 5> <Desc / Clms Page number 5>
Trois produits ont été utilisés : la vinblastine fournit par la société Sigma (réf. V 1377), le cisplatine fournit par la société Sigma (réf. P 4394) et le paclitaxel (taxolo) fournit par la société Sigma (réf. T 7402). Three products were used: vinblastine supplied by the company Sigma (ref. V 1377), cisplatin supplied by the company Sigma (ref. P 4394) and paclitaxel (taxolo) supplied by the company Sigma (ref. T 7402) .
Les animaux sont tondus sur le dos puis on place des produits à tester en solution dans de l'éthanol pur à raison de 25 % de concentration (p/1). Puis on réalise une dilution de cette solution au 1/200 par de l'huile d'amande douce. On obtient alors une concentration en produit actif de 0,5 %. The animals are shorn on the back and then products to be tested are placed in solution in pure ethanol at a concentration of 25% (w / 1). Then a 1/200 dilution of this solution is carried out with sweet almond oil. An active product concentration of 0.5% is then obtained.
0,2 ml de ces solutions sont déposées sur une gaze appliquée sur la peau et on dépose également un témoin obtenu en préparant le même solvant que celui qui a servi à dissoudre les principes actifs. On laisse les produits et le témoin en contact avec la peau pendant 15 minutes, puis on enlève la gaze. Le traitement est effectué pendant deux jours à raison de trois applications par jour à quatre heures d'intervalle. 0.2 ml of these solutions are deposited on a gauze applied to the skin and a control is also deposited obtained by preparing the same solvent as that which served to dissolve the active ingredients. The products and the control are left in contact with the skin for 15 minutes, then the gauze is removed. The treatment is carried out for two days at the rate of three applications per day at four hours apart.
On évalue ensuite la différence entre le temps moyen mis par le poil pour pousser sur les parties traitées et les parties témoins. The difference between the average time taken by the hair to grow on the treated parts and the control parts is then evaluated.
Pour les trois produits utilisés, on constate une différence de plus de deux mois. For the three products used, there is a difference of more than two months.
Le produit le plus efficace est la vinblastine pour lequel il y a pousse du poil intense sans irritation. Le cisplatine provoque une irritation modérée avec une pousse également modérée. Le paclitaxel provoque une pousse comparable à la vinblastine mais avec une importante irritation qui se prolonge plusieurs jours.The most effective product is vinblastine for which there is intense hair growth without irritation. Cisplatin causes moderate irritation with also moderate growth. Paclitaxel causes growth comparable to vinblastine but with significant irritation that lasts for several days.
Claims (7)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0108399A FR2826261B1 (en) | 2001-06-26 | 2001-06-26 | TOPICAL COMPOSITION COMPRISING A CYTOTOXIC PRODUCT AND ITS USE IN THE TREATMENT OF ALOPECHE |
| PCT/FR2002/002220 WO2003000208A1 (en) | 2001-06-26 | 2002-06-26 | Topical composition comprising a cytotoxic product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0108399A FR2826261B1 (en) | 2001-06-26 | 2001-06-26 | TOPICAL COMPOSITION COMPRISING A CYTOTOXIC PRODUCT AND ITS USE IN THE TREATMENT OF ALOPECHE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2826261A1 true FR2826261A1 (en) | 2002-12-27 |
| FR2826261B1 FR2826261B1 (en) | 2005-03-25 |
Family
ID=8864767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR0108399A Expired - Fee Related FR2826261B1 (en) | 2001-06-26 | 2001-06-26 | TOPICAL COMPOSITION COMPRISING A CYTOTOXIC PRODUCT AND ITS USE IN THE TREATMENT OF ALOPECHE |
Country Status (2)
| Country | Link |
|---|---|
| FR (1) | FR2826261B1 (en) |
| WO (1) | WO2003000208A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2879444B1 (en) * | 2004-12-22 | 2007-05-18 | Oreal | USE OF A COMPOUND CAPABLE OF INCREASING THE GLUTATHION RATE IN MELANOCYTES FOR THE TREATMENT OF CANITIS |
| ATE511836T1 (en) * | 2005-04-29 | 2011-06-15 | Univ Johns Hopkins | METHOD FOR SUPPRESSING SKIN CARCINOGENESIS INDUCED BY UV LIGHT |
| FR2902325B1 (en) * | 2006-06-20 | 2009-12-04 | Oreal | USE OF 3H-1,2-DITHIOLE-3-THIONE, ANETHOLE DITHIOMLETHIONE, SULFORAPHE, PHENETHYL ISOTHIOCYANATE, 6-METHYL-SULPHINYL) HEXYL ISOTHIOCYANATE AND ALLYL ISOTHIOCYANATE FOR THE TREATMENT OF CANITIA |
| FR2902329B1 (en) * | 2006-12-19 | 2011-07-01 | Oreal | USE OF SULFORAPHANE, PHENETHYL ISOTHIOCYANATE, 6-METHYL-SULPHINYL) HEXYL ISOTHIOCYANATE AND ALLYL ISOTHIOCYANATE FOR THE TREATMENT OF CANITIA. |
| CN101897691B (en) * | 2009-05-31 | 2013-06-05 | 无锡杰西医药科技有限公司 | Application of isothiocyanate compounds in promoting hair growth |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4571335A (en) * | 1983-06-17 | 1986-02-18 | Taylor Robert C | Method of inhibiting herpetic lesions by the use of platinum coordination compounds |
| EP0428754A1 (en) * | 1989-06-12 | 1991-05-29 | Shiseido Company Limited | Hair growth stimulant |
| WO1991014424A1 (en) * | 1990-03-28 | 1991-10-03 | Yunis Adel A | Methods for protecting against chemotherapy-induced hair loss |
| US5077055A (en) * | 1989-01-20 | 1991-12-31 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Topical therapeutic system comprising 5-fluorouracil |
| US5212303A (en) * | 1985-04-11 | 1993-05-18 | Centre International De Recherches Dermatologiques (Cird) | Benzonaphthalene derivatives, a process for their preparation and their use in therapeutic and cosmetic compositions |
| WO1997042964A1 (en) * | 1996-05-14 | 1997-11-20 | Universal Biolog Enterprises I | Method and product for promoting hair growth and treating skin conditions |
| WO2001012229A1 (en) * | 1999-08-17 | 2001-02-22 | Ivax-Cr A.S. | Pharmaceutical compositions for oral and topical administration |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0117878B1 (en) * | 1983-03-01 | 1986-07-09 | Rudolf Dr. Trensch | Product and method for the treatment of the hair |
| EP0227799A4 (en) * | 1985-06-20 | 1987-10-05 | Farmacon Inc | Allyl isothiocyanate and use thereof to inhibit hair loss. |
| JPH03153614A (en) * | 1989-11-09 | 1991-07-01 | Minato Sangyo Kk | Hair tonic |
| MXPA02010866A (en) * | 2000-05-05 | 2003-07-14 | Wisconsin Alumni Res Found | Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy. |
-
2001
- 2001-06-26 FR FR0108399A patent/FR2826261B1/en not_active Expired - Fee Related
-
2002
- 2002-06-26 WO PCT/FR2002/002220 patent/WO2003000208A1/en not_active Ceased
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4571335A (en) * | 1983-06-17 | 1986-02-18 | Taylor Robert C | Method of inhibiting herpetic lesions by the use of platinum coordination compounds |
| US5212303A (en) * | 1985-04-11 | 1993-05-18 | Centre International De Recherches Dermatologiques (Cird) | Benzonaphthalene derivatives, a process for their preparation and their use in therapeutic and cosmetic compositions |
| US5077055A (en) * | 1989-01-20 | 1991-12-31 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Topical therapeutic system comprising 5-fluorouracil |
| EP0428754A1 (en) * | 1989-06-12 | 1991-05-29 | Shiseido Company Limited | Hair growth stimulant |
| WO1991014424A1 (en) * | 1990-03-28 | 1991-10-03 | Yunis Adel A | Methods for protecting against chemotherapy-induced hair loss |
| WO1997042964A1 (en) * | 1996-05-14 | 1997-11-20 | Universal Biolog Enterprises I | Method and product for promoting hair growth and treating skin conditions |
| WO2001012229A1 (en) * | 1999-08-17 | 2001-02-22 | Ivax-Cr A.S. | Pharmaceutical compositions for oral and topical administration |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2826261B1 (en) | 2005-03-25 |
| WO2003000208A1 (en) | 2003-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1870081B1 (en) | Use of ellagic acid for treating graying hair | |
| WO1997003638A1 (en) | Hair care composition containing minoxidil and having a low fatty solvent content | |
| EP1753393B1 (en) | Method for the innoformulation of a biocompatible galenic base | |
| FR2684300A1 (en) | COSMETIC OR PHARMACEUTICAL COMPOSITION, PARTICULARLY DERMATOLOGICAL, IN PARTICULAR FOR PROMOTING THE PIGMENTATION OF SKIN OR HAIR, CONTAINING A BALLOTE EXTRACT, AND METHOD FOR PRODUCING THE SAME. | |
| EP0655235B1 (en) | Slimming composition | |
| EP3142682A1 (en) | Association of a tetrapeptide and a glyceryl ester for treating androgenic alopecia | |
| FR2848846A1 (en) | COSMETIC USE OF ASCORBIC ACID DERIVATIVES AS BLANCHING AGENTS | |
| CA2284387A1 (en) | Use of peptide preventing skin intolerance reactions, notably in cosmetic compounds | |
| EP2114387B1 (en) | Use of compositions containing at least one lignane and/or neolignane for modulating testosterone levels | |
| FR2826261A1 (en) | COMPOSITION FOR TOPICAL USE COMPRISING A CYTOTOXIC PRODUCT AND ITS USE IN THE TREATMENT OF ALOPECHE | |
| EP0243248A1 (en) | Compositions for the treatment of baldness and alopecia | |
| EP0751759B1 (en) | Minoxidil-based capillary lotion | |
| EP0595949B1 (en) | Compositions for the pigmentation of the skin or of the hair containing an extract of marrubium vulgare | |
| EP1885323B1 (en) | Cosmetic use of at least one natural ac-n-ser-asp-lys-pro-tetrapeptide or one of its analogues as agent for slowing down loss of hair and/or stimulating hair growth | |
| EP1404327B1 (en) | Dermatological composition comprising nicotinic acid or an amide, and a sphingoid base | |
| EP2705050B1 (en) | Novel peptides that are modulators of the protein trf2 and compositions containing same | |
| CA2534135A1 (en) | Cosmetic use of a biguanide derivative as an anti-ageing active substance for the skin | |
| EP0841893B1 (en) | Combination of zinc salicylate and a serenoa repens extract for treating seborrhoea, and cosmetic skin care compositions containing same | |
| CA2534067A1 (en) | Use of a bigaunide derivative for protecting skin against uvb radiation | |
| FR3101243A1 (en) | Combination of Ciclopiroxolamine and Piroctone Olamine to fight dandruff | |
| WO2020020791A1 (en) | Lespedeza capitata extract for use in the field of hair care | |
| FR2867973A1 (en) | Capillary care composition, useful to e.g. treat alopecia, comprises Sabal, which is an extract of Serenoa serrulata in association with a vehicle | |
| FR2895238A1 (en) | USE OF A SORBITAN OXYALKYLENE ESTER FOR SOOTHING SCALP, AND METHOD FOR COSMETIC TREATMENT OF SCALP | |
| WO2002005779A1 (en) | Composition, in particular cosmetic, containing dhea and/or its precursors or derivatives, and a vitamin | |
| FR3032115A1 (en) | COMPOSITION COMPRISING AN ASSOCIATION OF NIOSOMES AND C-GLYCOSIDE DERIVATIVE, CROCUS SATIVUS EXTRACT AND / OR CROCUS SATIVUS FLOWER EXTRACT, FOR REGULATING SKIN PIGMENTATION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |
Effective date: 20060228 |